menu
    • menu

    Company profile for Radiance Biopharma

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Radiance Biopharma is committed to developing next-generation Antibody Drug Conjugates (ADCs) to address cancer and other unmet medical needs. Our experienced team, comprising industry veterans from large pharmaceutical and biotech sectors, is dedicated to transforming patient care. Our innovative pipeline includes RB-164, a 'First-in-class' ADC targeting ROR-1; RB-201, a fully human bispecific ADC targeting HER2 and TROP-2; a...
    Radiance Biopharma is committed to developing next-generation Antibody Drug Conjugates (ADCs) to address cancer and other unmet medical needs. Our experienced team, comprising industry veterans from large pharmaceutical and biotech sectors, is dedicated to transforming patient care. Our innovative pipeline includes RB-164, a 'First-in-class' ADC targeting ROR-1; RB-201, a fully human bispecific ADC targeting HER2 and TROP-2; and RB-203, a proprietary monoclonal antibody against membrane Hsp70. Through these advancements, Radiance Biopharma aims to improve outcomes for patients worldwide.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Radiance BiopharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Boston Place, Ste. 2600 Boston, MA 02108
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://radiancebio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    China-based Novatim notches New Deal with Another US biotech
    China-based Novatim notches New Deal with Another US biotech

    03 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/03/3144055/0/en/Radiance-Biopharma-Signs-Exclusive-License-For-First-In-Class-c-Met-EGFR-Targeted-Nano-Antibody-ADC.html

    GLOBENEWSWIRE
    03 Sep 2025
    Share Share
    Radiance Begins Phase 1 Trial of ROR-1 ADC for Cancer
    Radiance Begins Phase 1 Trial of ROR-1 ADC for Cancer

    15 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/15/3062176/0/en/Radiance-Announces-First-Patient-Dosing-in-Phase-1-Clinical-Trial-of-its-Next-Generation-ROR-1-Targeted-ADC-for-Hematologic-and-Solid-Malignancies.html

    GLOBENEWSWIRE
    15 Apr 2025
    Share Share
    Radiance gets FDA clearance for RB-164 Phase 1 trial for cancers
    Radiance gets FDA clearance for RB-164 Phase 1 trial for cancers

    01 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/01/3053574/0/en/REPEAT-Radiance-Announces-FDA-Clearance-of-IND-Application-for-a-Phase-1-Clinical-Trial-of-RB-164-an-ROR-1-Targeted-ADC-for-Hematologic-and-Solid-Malignancies.html

    GLOBENEWSWIRE
    01 Apr 2025
    Share Share
    Radiance gets FDA clearance for RB-164 Phase 1 trial on cancer
    Radiance gets FDA clearance for RB-164 Phase 1 trial on cancer

    31 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/31/3052547/0/en/Radiance-Announces-FDA-Clearance-of-IND-Application-for-a-Phase-1-Clinical-Trial-of-RB-164-an-ROR-1-Targeted-ADC-for-Hematologic-and-Solid-Malignancies.html

    GLOBENEWSWIRE
    31 Mar 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    China-based Novatim Notches New Deal with Another US Biotech

    Details:

    The agreement aims for the development and commercialization of RB-601 (KY-0301), a novel Antibody Drug Conjugate (ADC) comprising a Bispecific Nanobody targeting c-MET and EGFR.


    Lead Product(s): RB-601

    Therapeutic Area: Oncology Brand Name: KY-0301

    Study Phase: Phase I/ Phase IIProduct Type: Antibody-drug Conjugate

    Recipient: Novatim Immune Therapeutics

    Deal Size: $1,165.0 million Upfront Cash: $15.0 million

    Deal Type: Licensing Agreement September 03, 2025

    blank

    01

    Radiance Biopharma

    U.S.A
    arrow
    VMX
    Not Confirmed

    Radiance Biopharma

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RB-601

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Recipient : Novatim Immune Therapeutics

    Deal Size : $1,165.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    China-based Novatim Notches New Deal with Another US Biotech

    Details : The agreement aims for the development and commercialization of RB-601 (KY-0301), a novel Antibody Drug Conjugate (ADC) comprising a Bispecific Nanobody targeting c-MET and EGFR.

    Product Name : KY-0301

    Product Type : Antibody-drug Conjugate

    Upfront Cash : $15.0 million

    September 03, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Radiance Begins Trial for ROR-1 Targeted ADC in Blood and Solid Cancers

    Details:

    RB-164 is an ROR-1 targeted antibody drug conjugate, which is currently being evaluated for the treatment of hematologic and solid malignancies.


    Lead Product(s): RB-164

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Antibody-drug Conjugate

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 15, 2025

    blank

    02

    Radiance Biopharma

    U.S.A
    arrow
    VMX
    Not Confirmed

    Radiance Biopharma

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RB-164

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Radiance Begins Trial for ROR-1 Targeted ADC in Blood and Solid Cancers

    Details : RB-164 is an ROR-1 targeted antibody drug conjugate, which is currently being evaluated for the treatment of hematologic and solid malignancies.

    Product Name : Undisclosed

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    April 15, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Radiance Clears FDA IND for RB-164 ADC in Hematologic Cancers

    Details:

    RB-164 is an ROR-1 targeted antibody drug conjugate, which is currently being evaluated for the treatment of hematologic and solid malignancies.


    Lead Product(s): RB-164

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: IND EnablingProduct Type: Antibody-drug Conjugate

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 31, 2025

    blank

    03

    Radiance Biopharma

    U.S.A
    arrow
    VMX
    Not Confirmed

    Radiance Biopharma

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RB-164

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Radiance Clears FDA IND for RB-164 ADC in Hematologic Cancers

    Details : RB-164 is an ROR-1 targeted antibody drug conjugate, which is currently being evaluated for the treatment of hematologic and solid malignancies.

    Product Name : Undisclosed

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Inapplicable

    March 31, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Radiance Biopharma Enters Exclusive License for ROR-1 Targeted Antibody Drug Conjugate

    Details:

    Under the licensing agreement, Radiance will be responsible for the development and commercialization of SYS6005 (RB-164), a novel clinical stage ADC targeting ROR-1 for treating neoplasms.


    Lead Product(s): RB-164

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Antibody-drug Conjugate

    Recipient: Megalith Pharmaceuticals

    Deal Size: $1,165.0 million Upfront Cash: $15.0 million

    Deal Type: Licensing Agreement February 19, 2025

    blank

    04

    Radiance Biopharma

    U.S.A
    arrow
    VMX
    Not Confirmed

    Radiance Biopharma

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RB-164

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Recipient : Megalith Pharmaceuticals

    Deal Size : $1,165.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Radiance Biopharma Enters Exclusive License for ROR-1 Targeted Antibody Drug Conjugate

    Details : Under the licensing agreement, Radiance will be responsible for the development and commercialization of SYS6005 (RB-164), a novel clinical stage ADC targeting ROR-1 for treating neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody-drug Conjugate

    Upfront Cash : $15.0 million

    February 19, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Biocytogen Enters Agreement for Bispecific Antibody Drug Conjugate with Radiance Biopharma

    Details:

    Radiance has an option to license YH012, a first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate from Biocytogen, for worldwide therapeutic development.


    Lead Product(s): YH012

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Antibody-drug Conjugate

    Recipient: Biocytogen

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 08, 2024

    blank

    05

    Radiance Biopharma

    U.S.A
    arrow
    VMX
    Not Confirmed

    Radiance Biopharma

    U.S.A
    arrow
    VMX
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : YH012

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Recipient : Biocytogen

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Biocytogen Enters Agreement for Bispecific Antibody Drug Conjugate with Radiance Biopharma

    Details : Radiance has an option to license YH012, a first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate from Biocytogen, for worldwide therapeutic development.

    Product Name : Undisclosed

    Product Type : Antibody-drug Conjugate

    Upfront Cash : Undisclosed

    January 08, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search